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Abstract
Background: The study aimed to explore the sensitivity and specificity of a novel fast 16S rDNA PCR and
sequencing assay for the improved diagnosis of infective endocarditis (IE) in patients with suspected native
or prosthetic heart valve (HV) infection over a multi-year period at our cardiovascular center.
Methods: Sixty-eight patients were prospectively enrolled who underwent HV replacement for suspected or
confirmed IE between February 1, 2009 and September 1, 2014. Patient demographics, medical co-morbidities,
Duke’s criteria, culture results, and antibiotic therapy were collected by detailed chart reviews. Dual-priming
oligonucleotide primers targeted to 500 bps of the V1-V3 region of the 16S rRNA gene were used to perform
fast broad-range 16S rDNA PCR and Sanger sequencing on ribosomal DNA extracted from HV tissues. The
performance/diagnostic efficiency of the molecular test was evaluated against blood cultures and Gram stain
and culture of HV tissue in patients’ with definite IE according to Duke’s criteria.
Results: Fifty patients (73.5 %) had definite IE and another 8 (11.8 %) had possible IE according to Duke’s criteria.
Cardiac surgery was delayed an average of 15.4 days from the time of the patient’s last positive blood culture, and
appropriate antibiotic therapy was given in the pre-operative period. While 44/50 (88 %) patients had a positive
blood culture, HV tissue culture was only positive in 23 (46 %) of them. Molecular testing of all HV tissues had
sensitivity, specificity, NPV and PPV of 92, 77.8, 77.8 and 92 % compared to 44, 100, 39.1 and 100 % respectively
for culture for diagnosis of definite IE. For prosthetic HV tissue, 16S rDNA PCR had sensitivity of 93 % and specificity
of 83 % compared to 35 and 100 % respectively for culture. A literature review showed that the diagnostic accuracy
of our novel fast broad-range 16S rDNA PCR assay was similar or better than that of previously published studies.
Conclusions: This novel fast broad-range 16S rDNA PCR/sequencing test had superior sensitivity compared to
tissue Gram stain and culture for identifying underlying bacterial pathogen in both native and prosthetic valve
endocarditis.
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Background
Infective endocarditis (IE) has a high morbidity and
mortality, often requiring treatment in an intensive care
unit [1, 2]. The Duke criteria are used to diagnose IE
and may help determine whether cardiovascular surgery
may be required [3], with almost half (44.9 %) of patients
ultimately requiring valve surgery [2, 4]. Microbiologic
diagnosis in IE, which is a cornerstone of the Duke cri-
teria, has classically relied on traditional culture results
for isolation of a pathogen(s) from blood or affected
heart valve tissue. However, blood culture results are
negative in 9–13 % of patients and all cultures are nega-
tive in 5 % of patients [2, 5]. Negative culture results are
even more prevalent in patients with atypical organisms
and prosthetic valve IE due to difficulties in selecting ap-
propriate tissue [6–10]. The rates of culture-negative IE
with atypical or difficult to culture bacteria have recently
increased [2]. Identification of the causative pathogen is
important for targeting antimicrobial therapy as well as
determining prognosis.
Broad-range sequencing of bacterial 16S ribosomal
DNA represents an alternative approach for establishing
the underlying organism in IE. Since broad-range sequen-
cing does not rely on culturing the underlying organism, it
may be particularly useful for identifying pathogens that
aren’t readily cultured with current methods [7, 11]. Evi-
dence supporting the use of broad-range 16S rDNA PCR/
sequencing for molecular diagnosis in some cases series
show that heart valve PCR may improve microbiological
diagnosis of IE in up to 20 % of patients. Some authors
have even suggested it be made part of Duke’s diagnostic
criteria [12]. The routine molecular diagnosis of IE has so
far been evaluated in a small number of patients, primarily
in European centers [9, 13–20]. Because broad-range PCR
assays are prone to contamination [21], and primers
within the 16S rRNA gene may cross-react with human
DNA in clinical samples, we developed a novel, fast
broad-range 16S rDNA PCR using unique dual-priming
oligonucleotide (DPO) primer to try and increase the sen-
sitivity and specificity of molecular diagnosis of IE [22].
The performance of our novel 16S rDNA PCR/sequencing
test was then validated by comparing it with the results of
blood culture and Gram stain and culture of excision
heart valve tissue in patients with and without a clinical
diagnosis of IE. A literature review was also done in order
to compare our results to other similar published diagnos-
tic accuracy studies of other user-developed PCR assays
[9, 13–19, 23–30], and recently published evaluations of
commercial PCR tests [31, 32].
Methods
Study setting and patients
The Calgary Zone is one of the largest integrated health-
care jurisdictions in Canada, which provides patient care
services to an urban and rural population of ~1.5 million
people. From February 1, 2009 to September 1, 2014, 68
patients with suspected IE underwent valve replacement
surgery at the Division of Cardiovascular Surgery, Foothills
Medical Center, Calgary Zone, Alberta Health Services,
Canada. The cardiovascular service is a tertiary referral
centre in the western part of Canada that primarily pro-
vides patient care to Southern Alberta, but is also referred
patients from other adjacent provinces.
Patients were retrospectively reviewed after surgery
using a standardised data collection sheet. Clinical fea-
tures for all patients were collected, including: age, sex,
type of valve tissue, location of valve, all blood culture
results, tissue culture results, peak white blood cell
count (WBC), peak erythrocyte sedimentation rate
(ESR), and peak C-reactive protein (CRP). Additionally
history collected included; previous IE, prosthetic valve,
intravenous drug use, and other predisposing factors.
Antibiotic use in the peri-operative period and in rela-
tion to culture results was also recorded. We classified
patients as definite, possible, or rejected diagnosis of IE
based on the modified Duke’s criteria [3].
Laboratory setting and samples
Microbiology testing was performed by the Division of
Microbiology, Calgary Laboratory Services (CLS). CLS is
a large regional centralized laboratory that performs
diagnostic testing for the entire Calgary Zone, including
all ambulatory, hospitalized and long-term care patients.
CLS Microbiology performs complex testing on >1 mil-
lion individual patient samples per annum.
Cardiac surgeons collected heart valves under sterile
conditions during each operative procedure. Heart valves
were immediately placed into a sterile container and
promptly transported to the Calgary Laboratory Services
(CLS) microbiology laboratory within 2 h after excision.
Heart valve tissue was stored at −80 to −86 °C and
batched for DNA extraction.
Blood and heart valve cultures
All patients had blood cultures performed prior to the
prescription of antibiotics. Two separate sets of blood
cultures [BacT/Alert FA (Aerobic) and FN (Anaerobic)]
are routinely drawn when adult blood cultures are
ordered. Blood cultures were immediately transported to
CLS and placed into the BacT/Alert system, and con-
tinuously monitored for up to 4-days for growth. Blood
culture bottles that flagged positive in the instrument
were immediately removed and an aliquot removed,
pelleted and plated onto routine media including a
Columbia blood agar (BA), chocolate agar (CHOC),
MaConkey (MAC) agar, and Brucella blood agar (BBA)
for culture of both aerobic and anaerobic bacteria. Iso-
lates were identified using a combination of rapid
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phenotypic methods and MALDI-TOF (Vitek MS
MALDI-TOF, bioMérieux, Laval Que.).
Native heart valve tissue was aseptically disrupted in a
tissue grinder in 0.5 mL brain heart infusion (BHI)
broth. Prosthetic valves were covered in 2.5 mL BHI and
vortexed for 30 s. before and after sonication for 5 min.
After sonication, the BHI tube was centrifuged at
3000 × g relative centrifugal force for 15 min. and the
supernatant was discarded. The 0.5 mL sediment was
then re-suspended by vortexing for 15 s. Aliquots
(100 μL) of the prepared heart valve tissue sediments
were immediately inoculated into a BacT/Alert FA (Aer-
obic) and FN (Anaerobic) blood culture bottle and
placed into the BacT/Alert (bioMérieux, Saint-Lauren,
QC) cabinet for continuous incubation and monitor for
up to 7 days. A 20–30 μL drop of the sediment was
planted onto BA, CHOC and BBA agars for culture of
both aerobic and anaerobic bacteria. BA and CHOC
plates were routinely incubated in oxygen at 35 °C for
up to 7 days, while the BBA plate underwent anaerobic
incubation in an Anoxamat cabinet (Mart Microbiology,
Inc., Drachten, Netherlands) for the same period of time.
Blood culture bottles were terminally sub-cultured onto
all of the above media and the plates incubated for a fur-
ther 7 days. Fungal culture was also routinely performed
by inoculation of inhibitory mould agar (IMA) and brain
heart infusion agar (BHIA), and fungal plates were incu-
bated in 02 at 30 °C for up to 6 weeks. A separate piece
of heart valve tissue as well as the tissue sediment was
stored frozen at −86 °C for molecular testing.
Molecular methods
Each heart valve tissue was minced manually with sterile
scalpels before being placed into a sterile 1.5 mL micro-
centrifuge tube. DNA was extracted using the QIAamp
DNA Mini Kit protocol for tissues (QIAGEN, Hilden,
Germany). Briefly, the tissue was re-suspended in 180 μL
of digestion Buffer ATL (50 mM Tris HCl, 1 mM EDTA,
0.5 % SDS, pH 8.5) and 20 μL of 20 mg/mL Proteinase K
solution (QIAGEN). The samples were then briefly vor-
texed and incubated at 56 °C, in a 1400 rpm Eppendorf
thermomixer for a minimum of 2 h. DNA in the proteo-
lytic digest was further purified according to the manufac-
turer’s instructions. DNA was eluted in 150 μL of Buffer
AE. DNA eluate was stored at −20 °C until use.
Broad-range 16S rDNA PCR was performed using dual
priming oligonucleotide (DPO) primers previously de-
scribed by Kommedal et al. [33] including a forward
primer [16SDPO_F:AGAgTTTgATCMTGGCTCA-I-I-
I-I-I-AACGCT (M = A/C; I = deoxyinosine; lower case
letter denotes a locked nucleic acid)], and a reverse
primer [16SDPO_R:CGCGGCTGCTGGCA-I-I-I-A-I-
TTRGC (R = A/G; I = deoxyinosine)] purchased from
Exiqon (Worburn, MA). PCR was set up in a 25 μL
reaction volume with 5 μL of template DNA and
0.5 μL of each primer in a master mix that included
13 μL DNA-free water (Molzym, Bremen, Germany),
2.5 μL of 10× buffer (Minerva BioLabs, Berlin,
Germany), 2.5 μL of 2 mM each dNTP mix prepared
in-house, and 0.625 μL of 2U/μL Eub polymerase
(Minerva BioLabs). Standard Fast PCR was performed
in an ABI 9700 or Veriti thermocycler (Life Tech-
nologies, Carlsbad, CA) under the following cycling
conditions: 5 min. initial denaturation at 95 °C:,
followed by 40 cycles of 94 °C for 1 min., 62 °C for
30 s, and 72 °C for 1 min., with a final extension at
72 °C for 5 min. PCR product was then electropho-
resed on a 1.5 % agarose gel containing SYBRsafe
(Life Technologies). PCR products displaying a band
in the expected ~500–600 base pair region were then
purified by Exo-SAP-it (Affymetrix. Santa Clara, CA).
Molecular identification was done by Sanger sequen-
cing of the 16S rDNA product with the same DPO
primers used for PCR and BigDye Terminator v1.1 Cycle
Sequencing Kit (Life Technologies) on an ABI Prism
3130×L sequencer (Life Technologies). A BLAST search
against the IDNS Bacteria database (SmartGene IDNS,
Lausanne, Switzerland) was done to provide a defini-
tive identification of the organism to the species- or
genus-level using the identity scores outlined by CLSI
MM-18 [34].
Ethics
This study was reviewed and approved by the Conjoint
Health Research Ethics Board, University of Calgary
(Ethics ID No: REB14-0588).
Data analysis
Data was analyzed according to standard descriptive sta-
tistics. The sensitivity, specificity, positive and negative
predictive values were calculated using the clinical diag-
nosis of IE based on the modified Duke criteria as the
gold standard for diagnosis [3]. A true positive result
was defined as one in which the valve culture or PCR
sequencing was positive in a patient with a clinical diag-
nosis of IE. A false-positive result was one in which a
microorganism was recovered from a patient without IE.
A true negative culture was defined as a negative culture
or PCR result in a patient without IE. A false-negative
culture occurred when the PCR or culture was negative
in a patient with IE.
Results
Patient characteristics
Sixty-eight patients were included in this study. Table 1
outlines key patient characteristics. Most of the patients
were male (n = 52, 76.5 %), with mean age 53. One-third
of the patients had a prosthetic valve (n = 23, 33.8 %).
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According to the modified Duke’s criteria, 50 patients
(73.5 %) were diagnosed with definite IE and another 8
patients were classified as having possible IE. The
remaining ten patients were controls and didn’t have IE.
Blood and heart valve culture
All patients had at least three sets of blood cultures
drawn. Overall, any positive blood culture had a sensitiv-
ity of 77.6 % (45/58) and specificity of 100 % (10/10). In
patients with negative blood cultures, PCR identified the
microbiologic agent in 7/13 (54 %) patients. In patients
with definite IE, any positive blood culture had a sensi-
tivity of 88 % (44/50) and specificity of 94 % (17/18). In
patients with definite IE and negative blood cultures,
PCR identified the microbiologic agent in 5/6 (83 %)
patients (Staphylococcus lugdenensis, Streptococcus san-
guinis, Streptococcus dysgalactiae, Propionibacterium
acnes, and Escherichia coli).
Molecular testing of heart valve tissue
Table 2 shows the results of each patient’s blood culture,
and heart valve tissue Gram stain, culture and 16S
rDNA PCR result. Aortic valve replacement (40, 69 %)
was more common in our patients than mitral valve sur-
gery (18, 31 %). A total of 23 (33.8 %) patients had a
prosthetic valve. The organisms causing IE in our patient
cohort included: Streptococcus viridans group (21; 42 %),
Streptococcus agalactiae (3; 6 %), Enterococcus faecalis
(10; 20 %), Staphylococcus spp. (6; 12 %), Haemophilus
parainfluenzae (2; 4 %), Gram-negative bacilli (2; 4 %),
Propionibacterium acnes (1; 2 %), and Cardiobacterium
hominis (1; 2 %). For patients with definite IE, broad-
range 16S rDNA PCR/sequence agreed with blood or
tissue culture results in 37 (74 %), and resulted in a new
microbiologic diagnosis in 3 patients with identification
of; Streptococcus dysgalactiae, Propionibacterium. acnes,
and Staphylococcus lugdenensis. Additionally, 3 patients
with possible IE but negative blood and heart valve tis-
sue cultures had a positive PCR/sequencing results in-
cluding; Delftia tsuruhatensis, Streptococcus mitis, and
Acinetobacter junii. Clinical review of these 3 patients
determined that they had IE, rather than these being
false-positive PCR results. Finally, in one patient with a
rejected diagnosis of IE, PCR sequencing suggested
Enterococcus faecalis. In one patient with definite endo-
carditis, blood cultures suggested coagulase negative
Staphylococcus but sequencing identified Enterococcus
faecalis. This change would be expected to impact clin-
ical management. Finally, in 13 patients with definite
endocarditis the causative organism was clarified how-
ever the change would not be expected to impact the
management plan. Overall, bacterial broad-range 16S
rDNA PCR/sequencing contributed to the microbiologic
diagnosis of 31 % of patients.
Table 3 shows the diagnostic performance of broad-
range 16S rDNA PCR/sequencing compared to Gram
stain and heart valve bacterial culture in patients with
and without IE based on a definite diagnosis of IE.
Molecular testing of heart valve tissue was positive in 46
(92 %) patients and negative or inconclusive in 4 (8 %)
patients with definite IE. Most patients (n = 14; 78 %)
who didn’t fulfill criteria for clinical IE had a negative
ribosomal broad-range PCR result. Broad-range 16S
rDNA PCR/sequencing had a sensitivity of 92 % (46/50)
and specificity of 78 % (14/18). Tissue culture was posi-
tive in 23 patients and negative in 28, yielding a sensitiv-
ity of 46 % (23/50). Tissue gram stain was positive in 13
(26 %) of patients with confirmed IE.
When considering either definite or possible IE,
broad-range 16S rDNA PCR/sequencing has a sensitivity
of 84.4 % (49/58) and specificity of 90.0 % (9/10) com-
pared to 37.9 % (22/58) and 100 % (10/10) for tissue cul-
ture respectively. Diagnostic accuracy for broad-range
16S rDNA PCR/sequencing was 85.3 % compared to
44.1 % for tissue culture. There were 17 patients with
definite or possible prosthetic valve IE and PCR had sen-
sitivity of 59 % (10/17) and specificity of 83 % (5/6),
while tissue culture had respective values of 35 % (6/17)
and specificity of 100 % (7/7).
Effect of peri-operative antibiotic treatment
All patients with definite or possible IE were on appro-
priate antibiotics during the peri-operative period. On
average, cardiac surgery was delayed an average of
15.4 days from the time of the patient’s last positive
Table 1 Clinical characteristics for all included patients
Demographics Male (%) 52 (76.5 %)
Age (years) 53.0 +/− 14.4
Medical history Prosthetic valve 23 (33.8 %)
Previous endocarditis 4 (6.0 %)
Intravenous drug user 3 (4.4 %)
Laboratory data White Blood Cell count (×109/L) 13.8 +/− 6.4
Peak ESR (mm/h) 58.5 +/− 31.7
Peak CRP (mg/L) 118 +/− 94
Transthoracic Echo Performed 53 (77.9 %)
Trans-esophageal Echo Performed 63 (92.6 %)
Culture data Mean sets of Blood Cultures 3.7 +/− 2.8
Any positive blood culture 45 (66.2 %)
Percentage of positive blood
cultures
32.1 %
Mean time from last positive
blood culture until surgery (days)
15.4 +/− 24.7
Proportions are reported as number (percentage). Continuous variables are
reported as number +/− standard deviation. CRP C-reactive protein, ESR
erythrocyte sedimentation rate, L litre, mg/L milligram per litre, mm/h
millimeters per hour
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Table 2 Comparison of bacterial culture and ribosomal sequencing results
Duke’s criteria Cardiac tissue Tissue gram
stain






Definite MV GPC No growth No growth Positive Staphylococcus lugdenensis New
Definite MV Negative No growth No Growth Positive Streptococcus dysgalactiae
subsp. equisimilis
New
Definite PAV GPB Cons; broth only No growth Positive P. acnes New
Definite MV GPC S. Mitis No growth Positive Streptococcus sanguinis Change
Definite MV papillary
leaflet
Negative S. bovis group S. salivarius Positive S. gallolyticus subsp.
pasteurianis
Change
Definite AV GPC No growth S. bovis Positive S. gallolyticus subsp.
pasteurianis
Change
Definite MV Vegetation Negative No growth S. mitis Positive S. oralis/sanguinis Change
Definite AV Negative No growth S. salivarius Positive S. mitis group (S. cristatus/oralis/
mitis)
Change
Definite MV Negative No growth S. salivarius Positive S. mitis group (S. cristatus/oralis/
infantis)
Change
Definite AV vegetation Negative S. bovis group S. bovis Positive S. gallolyticus subsp. gallolyticus Change
Definite AV vegetation Negative No growth GGS Positive S. dysgalactiae subsp. equisimilis Change
Definite PAV Negative E. faecalis/CONS;
broth only
S. agalactiae Positive S. agalactiae Change
Definite AV vegetation Negative No growth S. mitis Positive S. sanguinis Change
Definite PMV GPC S. mitis group Group C Strep Positive S. dysgalactiae subsp. equisimilis Change
Definite AV GPC S. mitis group S. mitis Positive S. sanguinis Change
Definite PAV Negative No growth CoNS Positive E. faecalis Change
Definite MV Negative CoNS broth only CoNS Positive S. epidermidis Change
Definite MV Vegetation Mixed GPC No growth S. mitis Positive S. mitis None
Definite MV Negative S. agalactiae; broth
only
S. agalactiae Positive S. agalactiae None
Definite AV abscess Negative No growth S. mitis Positive S. mitis group (mitis/tigurinus) None
Definite AV abscess Negative Enterococcus
faecalis; broth only
E. faecalis Positive E. faecalis None
Definite MV Negative No growth Haemophilus
parainfluenzae
Positive H. parainfluenzae None
Definite AV Negative No growth Streptococcus
pneumoniae
Positive S. pneumoniae None
Definite AV Vegetation Positive E. faecalis E. faecalis Positive E. faecalis None
Definite MV GPC No growth S. mitis Positive S. mitis None
Definite AV Negative E. faecalis E. faecalis Positive E. faecalis None
Definite AV Negative No growth E. faecalis Positive E. faecalis None
Definite AV Negative No growth E. faecalis Positive E. faecalis None
Definite Aortic lesion Negative No growth Granulicatella adiacens Positive G. adiacens None
Definite AV GPC No growth E. faecalis Positive E. faecalis None
Definite AV Negative S. lugdenensis S. lugdenensis Positive S. lugdenensis None
Definite AV GPC No growth S. mutans Positive S. mutans None
Definite Aortic annulus Negative No growth S. mitis Positive S. mitis None
Definite AV Negative Cardiobacterium
hominis
C. hominis Positive C. hominis None
Definite AV leaflet Negative No growth S. agalactiae Positive S. agalactiae None
Definite MV Negative S. lugdenensis S. lugdenensis Positive S. lugdenensis None
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Table 2 Comparison of bacterial culture and ribosomal sequencing results (Continued)
Definite AV leaflet Negative E. faecalis E. faecalis Positive E. faecalis None
Definite MV vegetation Negative S. lugdenensis; broth
only
S. lugdenensis Positive S. lugdenensis None
Definite AV; left atrial
lesion
Negative S. aureus; broth
only
S. aureus Positive S. aureus None
Definite AV Negative No growth S. mitis Positive S. mitis/sanguinis None
Definite PAV Negative No growth S. salivarius Positive S. salivarius None
Definite AV Negative E. coli No growth Positive E. coli None
Definite MV vegetation GPB H. parainfluenzae H. parainfluenzae Positive H. parainfluenzae None
Definite MV Negative CoNS; broth only No growth Negative Not Done None
Definite MV Negative No growth E. faecalis Positive E. faecalis None
Definite Aorta Negative No Growth E. faecalis Positive E. faecalis None
Definite AV Negative No Growth S. aureus Negative Not done None
Definite AV Negative No Growth S. aureus Positive Mixed None
Definite AV vegetation Negative S. bovis S. bovis Positive S. bovis None
Definite AV Positive S. aureus S. aureus Negative Negative None
Possible PAV Negative No growth No Growth Positive Acinetobacter junii New
Possible AV Negative No Growth No Growth Positive Delftia tsuruhatensis New
Possible AV Negative No Growth No Growth Positive S. infantis New
Possible AV Negative No growth No growth Negative Negative None
Possible AV Negative No Growth No Growth Negative Negative None
Possible PAV Negative No Growth No Growth Negative Negative None
Possible AV Negative No Growth No Growth Negative Negative None
Possible AV Negative No Growth No Growth Negative Negative None
Negative AV Negative No Growth No Growth Positive E. faecalis New
Negative MV Negative No Growth No Growth Negative Negative None
Negative MV Negative No Growth No Growth Negative Negative None
Negative PMV Negative No Growth No Growth Negative Negative None
Negative AV Negative No Growth No Growth Negative Negative None
Negative AV Negative No Growth No Growth Negative Negative None
Negative AV vegetation Negative No Growth No Growth Positive Mixed None
Negative MV thrombus Negative No Growth No Growth Negative Negative None
Negative MV Negative No Growth No Growth Negative Negative None
Negative AV Negative No Growth No Growth Positive Mixed None
AV aortic valve, CoNS coagulase negative Staphylococcus, GBS group B Streptococcus, GCS group C Streptococcus, GGS group G Streptococcus, GPC gram positive
cocci, GPB gram positive bacilli, MV mitral valve, PAV prosthetic aortic valve, PMV prosthetic mitral valve. New indicates a new microbiologic diagnosis was made
based on bacterial sequencing results. Change indicates that the microbiologic agent was changed or clarified
Table 3 Performance of Gram stain and bacterial culture of heart valve tissue compared to 16S broad range PCR/sequencing for
diagnosis of endocarditis
Method Sensitivity Specificity PPV NPV Diagnostic efficiency
Gram Stain of Heart Valve Tissue 26.0 % (15.1–40.6) 100 % (78.1–100.0) 100 % (71.7–100.0) 32.7 % (21.0–46.8) 45.6 % (33.8–57.4)
Heart Valve Tissue Culture 46 % (33.0–59.6) 100.0 % (83.1–100.0) 100.0 % (83.1–100.0) 41.3 % (27.0–56.7) 60.2 % (50.8–68.0)
16S Broad Range PCR/Sequencing 92.0 % (84.6–96.5) 77.8 % (57.4–90.4) 92.0 % (84.6–96.5) 77.8 % (57.4–90.4) 88.2 % (77.4–94.9)
Diagnostic performance of tissue culture and 16S Broad Range PCR sequencing in 68 samples (i.e. 50 cases had Definite IE, 8 cases had Possible IE, and 10 Cases
were controls with no clinical or laboratory evidence of IE). Calculations are based on a definite diagnosis of endocarditis by the Duke’s criteria as the gold
standard for diagnosis. 95 % CI in brackets. PPV positive predictive value, NPV negative predictive value
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blood culture. Figure 1 shows that the prescription of
antibiotic therapy had no effect on the bacterial isolate
recovery from HV culture, or the ability of PCR/sequen-
cing to detect the presence of bacterial DNA in excised
heart valve tissue.
Literature review
Table 4 summarizes the results for most of the previously
published evaluation of user-developed broad-range 16S
rDNA PCR/sequencing for patients with definite IE ac-
cording to Duke’s criteria [9, 13–19, 23–28]. Only two
studies that focused on patients with blood culture-
negative endocarditis (BCNE) are included [29, 30]. In
addition, there are two small evaluations of commercial
molecular assays [31, 32]. A total of 824 patients with def-
inite IE, 759 patients with blood culture-negative endocar-
ditis, and 482 controls without IE have been studied using
a molecular diagnostic approach, mainly in European cen-
ters. Although most of the patients in these studies were
on antibiotics at the time of heart valve excision, only a
few documented the median duration of pre-operative
antibiotic treatment given prior to surgery. However, our
patients’ experience was similar to those in other studies;
at least two-weeks of antibiotics therapy had been given
prior to cardiac surgery. Although some studies found that
the duration of pre-operative antibiotics negatively effects
heart valve culture results [18, 25], that has not been con-
firmed by others [9]. Pre-operative blood cultures are
positive in most studies in approximately two-thirds
of patients (range 33.3–87.7 %) which was confirmed
in our patient population. However, heart valve cul-
ture had less optimal range of recovery of a pathogen
(range 11.2–32.3 %) across these studies compared to
either blood cultures or broad-range 16S rDNA PCR
on heart valve tissue. User-developed broad-range 16S
assays have also had a wide range of performance in
patients with definite IE with a sensitivity (range =
41.2–100 %), specificity (range = 61.5–100 %). PPV
(range = 79–100 %) and NPV (range = 34.4–100 %).
Some of this variability may be explained by differ-
ences in gold standards for diagnosis. In studies
where histology has also been reported, the highest
correlation occurred between the presence of IE on
histology and the HV PCR result [13, 15].
A wide range of primers that have different nucleo-
tide positions in the E. coli 16S rRNA gene have been
used in user-developed assays, which is part, may
explain the wide range in performance in previously
reported studies (Table 4). However, both commercial
assays also showed similar performance variability
(i.e., sensitivity 61 vs. 95 %) albeit the Septifast
(Roche) and UDM™ (Molyzym) assays have different
configurations, and have only been evaluated in very
small numbers of patients [31, 32].
Discussion
This is the first evaluation of a novel fast broad-range
16S rDNA PCR/sequencing assay in a Canadian patient
population, and the first study of the clinical utility of
DPO primers for the routine molecular analysis of heart
valve tissue in consecutive patients with and without in-
fective IE. Additionally, our study had the advantage of
extensive clinical information to better delineate the
Dukes minor criteria for all patients. Our study confirms
the higher sensitivity of molecular heart valve testing
compared to tissue culture [35–38]. However, our novel
assay has one of the highest reported sensitivities of a
user-developed broad-range 16S rDNA PCR to date. Al-
though pre-operative blood cultures make a microbio-
logic diagnosis in approximately two-thirds of patients
suspected of having IE, subsequent molecular analysis of
heart valve tissue contributed to the microbiologic diag-
nosis of 31 % of our patients. However, the change in
diagnosis would only be expected to contribute to the
clinical management of 13 % of patients. There was a
significant delay between first culture results and the
time of surgery, during which patients were universally
on antibiotics. This is known to interfere with culture
results but did not seem to significantly impair the diag-
nostic utility of molecular sequencing [39]. Broad-range
16S rDNA PCR/sequencing seems particularly useful in
patients with culture-negative IE, which has also been
reported recently by another center [38]. Additionally,
sequencing to the subspecies level, as we have done, has
important clinical implications in a small but important
subset of patients [40]. Therefore, bacterial broad-range
16S rDNA PCR/sequencing has a complementary role
with traditional culture techniques in the diagnosis of
potential IE.
In our study the specificity of broad-range 16S rDNA
PCR/sequencing was relatively lower than previous re-
ports, despite the use of DPO primers that have been
shown to substantially decrease cross-reactivity with
human DNA [35–38]. This may reflect occult infection
in patients who otherwise did not meet the Duke criteria
for infective endocarditis. This further supports the
suggestion of the addition of molecular diagnostics to
the Duke criteria [12]. Alternatively, this could reflect
sample contamination at the time of collection prior to
sequencing, or within one of the molecular test compo-
nents. Until the clinical role for broad-range 16S rDNA
PCR/sequencing is clarified positive PCR results in
patients who otherwise do not meet criteria for IE
should therefore be interpreted within the full clinical
context and correlated with all other laboratory results.
Prosthetic valve IE accounts for up to 20 % of cases of
IE and is associated with high rates of morbidity and
mortality [41], making microbiologic diagnosis especially
critical. As implantation of prosthetic valves increases,
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Table 4 Summary of heart valve 16S ribosomal PCR results from patients with definite IE according to Duke’s criteria: literature review

















Sensitivity Specificity PPV NPV
1 (Goldenberger, [8]) Switzerland NR b 18 14/18 (77.8 %) 8-806 2/18 (11.1 %) 11.1/100 % 93.3 % 66.7 % 93.3 % 66.7 %
2 (Gauduchon, [13]) France 31.5 (range, 8 to 150) 29/23 c 21/29 (72.4 %) 911-930 and 1390-1371 27/29 (93.1 %) c NR ND ND ND ND
3 (Lang, [19]) UK NR d 28/61 20/28 (71.4 %) 1522-1540 and 1170-1189 14/20 (70 %) NR ND ND ND ND
4 (Breitkopf, [23]) Germany NR 51/16 7/21 (33.3 %) 8-27 and 907-926 None 7.8/93.7 % 41.2 % 100 % 100 % 34.8 %
5 (Greub, [15]) France NR 127/118 57/127 (44.9 %) 536-1050 14/68 (20.6 %) 13/98 % 61 % 100 % 100 % 74 %%
6 (Rovery, [24]) France 19.5 (range, 1–150) 147 NR 536-1050 64/95 (67 %) e NR ND ND ND ND
7 (Kotilainen, [18]) Finland 19.6 (range 1–58d) 28/18 20/28 (71.4 %) 1054-1077 and 1950-1926 18/25 (72 %) 13.1/100 % 43.1 % 100 % 100 % 58.1 %
8 (Marin, [9]) Spain 10 (range, 1–25) 35/120 31/35 (88.6 %) 783-806 and 1389-1370 16/35 (45.7 %) 24.3/56.4 % 96 % 95.3 % 98.4 % 88.5 %
9 (Volstedlund, [25]) Denmark 19.3 (range, 0–90) 57/10 50/57 (87.7 %) 341-534 19/57 (33.3 %) 26/62 % 72 % 100 % 100 % 62 %
10 (Fournier, [30]) g France NR 549/191/19 All patients had
negative blood
culture
Same as study (2) 536F
and RP2
45.6 % 45.7 %/NR 69.2 % ND ND ND




100 % 100 % 79 % 100 %
12 (Vondracek, [27]) Sweden NR 57/61 48/57 (84 %) 334-939 20/57 (35.1 %) 23/87 % 77 % 100 % 100 % 87 %
13 (Boussier, [28]) f France NR 31 23/31 (74.2 %) Same as (2) and 8-27
and 1510-1492
5/31 (16.1 %) 32.3/100 % 78 % 100 % 100 % 61.5 %
14 (Kemp, [17]) Denmark NR 56/36 36/56 (64.3 %) 8-534 7/42 (16.7 %) 16.7/100 % 88 % 61.5 % 88 % 57.1 %
15 (Sadaka, [29]) g Egypt NR 19 All blood cultures
were negative
1522-1540 and 1170-1189 5/6 (83.3 %) 62.5 %/NR ND ND ND ND
16 (Harris, [16]) Ireland, UK NR 47 35/47 (74.5 %) 16S Fa, 16S Fb and 16SR
(320 bp)
29/47 (61.7 %) NR 67 % 91 % 96 % 46 %
17 (Leli, [31])h Italy NR 20 NR Septifast (Roche) 3/19 (15.8 %) 15.8/100 % 95 % 100 % 100 % 83.3 %
18 (Marsch, [32]) i Germany NR 46 NR UMD™, Molzym 27/46 (56.7 %) 32.1/100 % 61 % ND ND ND
aOnly data for definite IE cases is included. Some studies (3, 7, and 9) also enrolled a small number of cases with possible IE according to Duke’s criteria. Controls were patients undergoing cardiac surgery for non-infective reasons
bNot reported (NR)
cDefinite IE was diagnosed by histology in the 52 cases; 29 definite IE cases were included and 23 cases with no evidence of IE on histology of heart valve tissue. PCR results were compared to histology and not
culture in this study
dCases divided into an active group (n = 19) that was on antimicrobial therapy at the time of surgery, and the resolved group (N = 9) who had completed treatment (time period 3 months to 7 years after treatment
at the time of cardiac surgery, and nine others with possible IE
eBacterial DNA was amplified by PCR significantly more often (64/95, 67 %) in HV with histological evidence of IE than valves that had no histological evidence of IE (21/55, 38 %) (p = 0.001)
fThis study used a two-step PCR procedure: first, a real-time method, then a conventional end-point PCR was applied to HV samples to improve the sensitivity of molecular detection from 38 to 58 %
gBoth of these studies only enrolled patients with culture negative endocarditis (i.e., all patients had clinical evidence of IE but negative blood cultures)
hPCR on heart valve tissue was performed using a commercial real-time PCR assay (SeptiFast, Roche Molecular Systems, Mannheim Germany)














this group of patients will become increasingly import-
ant [42]. Previous investigations looking at PCR sequen-
cing in patients with mechanical or bio-prosthetic valves
showed poor diagnostic performance [5, 36]. Given the
limited specimen available from prosthetic valves, sam-
pling error is an important source of diagnostic error.
Sequence amplification requires smaller samples, making
sequencing potentially less prone to sampling errors
than bacterial culture or histologic analysis [5]. In our
study, the sensitivity of broad-range 16S rDNA PCR/
sequencing in prosthetic valves was lower compared
to its performance in native valves but still outper-
formed tissue culture.
Our study has several important limitations. We are
reporting the experience from a single centralized la-
boratory that has accrued experience in the development
and implementation of complex user designed molecular
assays. The results reported herein may not reflect the
accuracy of the utilization of this technology in jurisdic-
tions without expertise in broad-range 16S rDNA PCR/
sequencing. Additionally, our case series is limited by
selection bias, since only patients undergoing valve sur-
gery were included in our study. While this limits the
generalizability of our study, it accurately reflects routine
sequencing of excised heart valve tissue. Finally, the
Duke criteria that we used as the gold standard for diag-
nosis are reliant on tissue and blood culture as diagnos-
tic criteria, which may lead to overestimates of their
diagnostic performance.
Conclusion
Identification of the underlying microbial pathogen in
endocarditis is crucial to determining length of therapy
and appropriately targeting anti-microbial. Bacterial se-
quencing to the subspecies level improves pathogen
identification, and has important clinical implications.
Broad range sequencing performed well as a diagnostic
test, contributing the clinical care of 13 % of patients,
compared to a gold standard of clinical diagnosis based
on Dukes criteria. This procedure should be considered
an essential step in the management of all patients with
suspected or possible infective endocarditis, particularly
in patients with culture negative IE.
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